Skip to main content
Access Bio, Inc. logo

Access Bio, Inc. — Investor Relations & Filings

Ticker · 950130 ISIN · KR8840090003 LEI · 335800Q5TV77F4L9Q648 KO Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2024-12-11 Major Shareholding Noti…
Country IN India
Listing KO 950130

About Access Bio, Inc.

https://accessbio.net/

Access Bio, Inc. is a company dedicated to the prevention and early diagnosis of infectious diseases through the research, development, and manufacturing of in vitro diagnostic solutions. Its portfolio includes rapid diagnostic tests (RDTs), immunochemical diagnostics, biosensors, and molecular diagnostic products. The company is recognized for commercializing high-quality tests to combat significant global health threats, including malaria, COVID-19, HIV, and HPV. With a large-scale manufacturing capacity, Access Bio distributes its products globally, serving as a key partner in global health, particularly in the fight against often-neglected diseases.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by a major shareholder (PharmGen Science) in the company Access Bio. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-12-11 Korean
기타경영사항(자율공시) (제23기 정기주주총회 권리주주 확정을 위한 증권예탁증권 기준일 설정 공고)
AGM Information Classification · 1% confidence The document is a regulatory announcement regarding the setting of a record date for the 23rd Annual General Meeting (AGM) to determine shareholder voting rights. It is a short, formal notice (under 5,000 characters) announcing a procedural step related to an upcoming meeting rather than the meeting materials themselves or a financial report. As it does not fit into specific categories like AGM-R (presentation) or PSI (proxy solicitation), it falls under the general regulatory announcement category.
2024-12-10 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for Access Bio, Inc. covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial statements, management discussion and analysis, and operational data, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
전환가액의조정 (제5회차)
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the adjustment of the conversion price for convertible bonds (CB). It details the change in conversion price, the number of convertible shares, and the underlying calculation methodology due to market price fluctuations. This falls under capital structure changes and financing updates, specifically related to convertible securities. Among the provided categories, 'CAP' (Capital/Financing Update) is the most accurate classification for adjustments to convertible debt instruments.
2024-11-11 Korean
전환가액의조정 (제5회차)
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing from Access Bio regarding the adjustment of the conversion price for its 5th series convertible bonds. It details the change in conversion price, the number of shares affected, and the underlying calculation methodology based on market price fluctuations. This falls under capital structure changes and financing updates, specifically related to convertible debt instruments, which is best classified as CAP (Capital/Financing Update).
2024-10-10 Korean
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구) (수수료 계약 부재 확인을 위해 제기한 당사의 소송에 대한 피고의 반대소송)
Legal Proceedings Report Classification · 1% confidence The document is a regulatory filing from Access Bio regarding a legal proceeding (a counterclaim/lawsuit). It details the nature of the litigation, the claim amount, and the company's response. This falls under the category of legal proceedings and regulatory disclosures regarding litigation.
2024-09-27 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.